7 August 2020 Malaysia Malaysia Wants To Extend Compulsory Licence For Hepatitis C Drug Remdesivir is not in the Malaysian treatment protocol for Covid-19, says Dr Adham Baba.
29 July 2020 Malaysia Klang MP Wants Compulsory Licencing For Remdesivir Covid-19 Treatment Charles Santiago says Malaysians can’t afford the total remdesivir price of RM10,000 per patient.
2 July 2020 World US Grabs Almost All Remdesivir Supplies Gilead has allowed nine manufacturers of generic drugs to distribute remdesivir to 127 poor and developing countries.
26 May 2020 Opinion What Is A Covid-19 Cure Worth? Compulsory licencing may not necessarily guarantee widespread access of remdesivir to Covid-19 patients in Malaysia.
22 May 2020 Letter There Is No Reason To Accept High Prices For Covid-19 Treatments — Mark Cheong Wall Street analysts suggest remdesivir could be priced between US5,000-US10,000 for a 10-day course of treatment.
21 May 2020 Malaysia Malaysia To Use ‘Other Means’ Of Getting Remdesivir If Effective For Covid-19 Gilead Sciences has excluded Malaysia from receiving generic versions of remdesivir.
21 May 2020 Malaysia Malaysia Not Rich, Affordable Remdesivir Needed, MPs Tell Gilead Three Opposition MPs say Malaysia can’t afford to spend as much on health care as Singapore or other Asian countries like South Korea.
20 May 2020 Malaysia Why Malaysia May Lose Generic Access To Potential Covid-19 Drug The only three Asean countries excluded by Gilead Sciences for generic versions of remdesivir in its new licencing agreements are Malaysia, Singapore, and Brunei.
19 May 2020 Letter Include Malaysia And Other Middle-Income Countries in All Licensing Agreements For Covid-19 Diagnostics, Treatments, And Vaccines — MHC & DNDi Gilead excluded Malaysia, among other middle-income countries, from distribution of Remdesivir to 127 nations under voluntary licensing.
12 May 2020 World Expensive Future Covid-19 Medicine Will Worsen Inequality: Study Unwarranted high prices for medications could lead to preventable deaths, said a study.